Clinical trials: sponsored by Federico II University
Acromegaly
Prediction of Tumor Shrinkage in Acromegaly
In the last two decades, somatostatin analogs have become a cornerstone of medical therapy for acromegaly. One year of treatment with octreotide-LAR (LAR) controls GH and IGF-I excess in 54% and 63% of unselected patients, with…
- Trial name
- NCT00616408
- Testing
- Octreotide-LAR
- Where
- Italy
- Volunteers
- 61 people
- Sponsor
- Federico II University
Acromegaly
Cardiovascular Outcome After Surgery or Somatostatin Analogues
A direct comparison between the results of surgery or somatostatin analogues (SSA) on cardiovascular complication in acromegaly has never been performed.
- Trial name
- CVAcro (NCT00615004)
- Where
- Italy
- Volunteers
- 215 people
- Sponsor
- Federico II University
Polycystic Ovary Syndrome
Oral Contraceptive and Cardiovascular Risk in PCOS
Oral contraceptive therapy is routinely used for the treatment of menstrual disturbances of patients with polycystic ovary syndrome (PCOS).
- Trial name
- NCT00593294
- Testing
- Physical exercise, OC - Drospirenone plus Ethynylestradiol, Vitamin, polyvitamins tablets
- Where
- Italy
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Federico II University
Hypopituitarism, Pituitary Tumors
Effect of 5 Years of GH Replacement on Atherosclerosis
Adult patients with hypopituitarism under adequate conventional hormone replacement therapy have reduced life expectancy due to excess vascular events (1-4).
- Conditions
- Hypopituitarism, Pituitary Tumors, Growth Hormone Deficiency
- Trial name
- 5yrGH (NCT00462475)
- Testing
- Recombinant Growth Hormone, Genotropin (Pfizer)
- Where
- Italy
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Federico II University
Cystic Fibrosis, Glucose Metabolism Disorders
One Year Glargine Treatment in CFRD Children and Adolescents
Glargine treatment can improve the clinical features in Cystic Fibrosis patients affected by glucose derangements
- Trial name
- NCT00483769
- Testing
- Glargine
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Federico II University
Acromegaly
Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly
Epidemiological data indicate that patients with active acromegaly have reduced life expectancy because of cardiovascular (60%) and respiratory diseases (25%) mainly (1-10).
- Trial name
- HDacro (NCT00461149)
- Testing
- Octreotide-LAR
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Federico II University